Epstein Secrets

pment. So what should be done? The United States government has created myriad special pricing arrangements that pervert incentives. For instance, Medicaid generally gets the lowest prices in the market. This discourages drug companies from experimenting with other payers on lower price arrangements, kn

huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a third or a half, there would be sufficient incentive to assume th

hich re- quired about 135 employ at capacity, now has about ?Cl patients. Peck said. Most of therm both adults and children, are long-term and on Medicaid, she said. SEW represents about 16,000 health-care workers in Florida and the South- eastern United States. Obc" dpotoRobcost com BANKRUPTCY •

. To earzictapoiattlire MARSHALL DAVID RIDLON MarsNall David Ridlon, 41 of West Palm Beach, dad aside June 2 2009. Mansholt was born in , .23 Merck 4, 1968. He has been • reedoia Mona sin 1979. &swag Marshall is As mother, Cindy of NC; his faker Mt (Ann) of Upsets; a brother. Sam gale and the

oval process for generic biologics and granting exclusive marketing rights to original manufacturers for 12 years, (iv) increased drug rebates to the Medicaid program, and (v) disclosure requirements for financial relationships between various healthcare entities. Within the U.S., the pharmaceutical indust

) and Tioga. He was previously on the boards of Intarcia Therapuetics (now currently a Board observer), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and